|
Glaucoma - Current and Future Players |
May 11 2015 |
95 |
Global |
$2,995.00 |
|
|
Glaucoma - US Drug Forecast and Market Analysis to 2023 |
May 11 2015 |
241 |
USA |
$4,995.00 |
|
|
Glaucoma - 5EU Drug Forecast and Market Analysis to 2023 |
May 11 2015 |
245 |
Europe |
$6,995.00 |
|
|
Dyslipidemia - Japan Drug Forecast and Market Analysis to 2023 |
May 5 2015 |
252 |
Japan |
$4,995.00 |
|
|
Dyslipidemia - US Drug Forecast and Market Analysis to 2023 |
May 5 2015 |
254 |
USA |
$4,995.00 |
|
|
Dyslipidemia - China Drug Forecast and Market Analysis to 2023 |
May 5 2015 |
252 |
China |
$4,995.00 |
|
|
Dyslipidemia - 5EU Drug Forecast and Market Analysis to 2023 |
May 5 2015 |
267 |
Europe |
$6,995.00 |
|
|
Dyslipidemia - Current and Future Players |
May 5 2015 |
120 |
Global |
$2,995.00 |
|
|
Fibromyalgia - 5EU Drug Forecast and Market Analysis to 2023 |
May 1 2015 |
143 |
Europe |
$6,995.00 |
|
|
Fibromyalgia - Current and Future Players |
May 1 2015 |
64 |
Global |
$2,995.00 |
|
|
Fibromyalgia - Japan Drug Forecast and Market Analysis to 2023 |
May 1 2015 |
133 |
Japan |
$4,995.00 |
|
|
Fibromyalgia - US Drug Forecast and Market Analysis to 2023 |
May 1 2015 |
134 |
USA |
$4,995.00 |
|
|
Melanoma - 5EU Drug Forecast and Market Analysis to 2023 |
Apr 5 2015 |
281 |
Europe |
$6,995.00 |
|
|
Melanoma - Australia Drug Forecast and Market Analysis to 2023 |
Apr 5 2015 |
261 |
Australia |
$4,995.00 |
|
|
Melanoma - US Drug Forecast and Market Analysis to 2023 |
Apr 5 2015 |
263 |
USA |
$4,995.00 |
|
|
Melanoma - Japan Drug Forecast and Market Analysis to 2023 |
Apr 5 2015 |
257 |
Japan |
$4,995.00 |
|
|
Melanoma - Current and Future Players |
Apr 5 2015 |
91 |
Global |
$2,995.00 |
|
